# TAS-102 Combined With Bevacizumab for Second-line Maintenance Treatment of Advanced Colorectal Cancer

> **NCT06293014** · PHASE2 · RECRUITING · sponsor: **Henan Cancer Hospital** · enrollment: 224 (estimated)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** TAS-102+bevacizumab
- **DRUG:** Standard chemotherapy+bevacizumab

## Key facts

- **NCT ID:** NCT06293014
- **Lead sponsor:** Henan Cancer Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-02-23
- **Primary completion:** 2025-10-15
- **Final completion:** 2026-11-28
- **Target enrollment:** 224 (ESTIMATED)
- **Last updated:** 2024-03-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06293014

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06293014, "TAS-102 Combined With Bevacizumab for Second-line Maintenance Treatment of Advanced Colorectal Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06293014. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*